Engineered 'Living Drug' with emergency 'Off Switch' tested for tough leukemia cases
NCT ID NCT03016377
Summary
This study is testing a new type of treatment for people whose acute lymphoblastic leukemia (ALL) has come back or hasn't responded to other therapies. Doctors take a patient's own immune cells (T cells), genetically modify them to better find and attack leukemia cells, and add a safety switch that can deactivate the cells if severe side effects occur. The main goals are to see if this treatment is safe and to find the best dose for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.